How will Pharma Harness Big Data to Address Unmet Medical Needs?
I was excited to join representatives of other innovative companies on a digital health panel exploring how emerging technologies and information streams can have a hugely beneficial effect on patient programs and outcomes. The panel took place 4/7 at eyeforpharma in Philadelphia at the Hilton Penn's landing.
The panel tackled a number of questions posed by moderator David Davidovic, former head of commercial operations at Genentech. The audience was engaged and interactive posing questions around how to drive innovation within a life sciences organization, to how to collaborate and share knowledge and best practices. Ultimately everyone on the panel agreed that data needs to be removed from their silos in order to be relevant, useful and actionable.
Just as the pharmaceutical industry is under heavy pressure to reduce R&D costs and speed time to market for new products, new life sciences data-driven applications are enabling pharmaceutical organizations to be more customer and patient-centric.
Easier access to the latest information is at the heart of the ongoing transformation in this critical discipline. After Reltio's public launch and announcement of Series A funding and public launch of Reltio Cloud and built-in data-as-a-service (DaaS), we have seen tremendous interest from both partners and life sciences organizations seeking better ways to acquire and manage their data.
For example, a new partnership with DMD, a pioneer in healthcare digital communications and connectivity, provides on demand access to the most comprehensive database and up-to-date physician emails directly from within Reltio Data-driven applications. DMD joins Enclarity and Health Market Science (both now LexisNexis), MedPro and DarkMatter2BD as partners delivering their data through Reltio DaaS.
The media has also taken notice, we were honored to be recently cited by PharmaVOICE as an innovator disrupting the healthcare landscape, alongside such marquee names as Google and GE Healthcare. Analysts at Constellation Research and 451 Research have also profiled Reltio’s technology as pioneering and disruptive.